Johnson & Johnson Faces $40 Million Verdict in Talc Cancer Lawsuit Amidst Ongoing Legal Battles
A Los Angeles jury awarded $40 million to two women for ovarian cancer caused by Johnson & Johnson's talcum powder, amidst ongoing legal challenges and appeals.
Boston HeraldTicker: Jury says Johnson & Johnson owes $40 million to 2 cancer patients who used talcum powders
ABC NewsJury says Johnson & Johnson owes $40M to 2 cancer patients who used talcum powders
Chicago TribuneJury says Johnson & Johnson owes $40 million to 2 cancer patients who used talcum powders
Associated PressJury says Johnson & Johnson owes $40 million to 2 cancer patients who used talcum powders
Overview
A Los Angeles jury awarded $40 million to two women, Monica Kent and Deborah Schultz, for ovarian cancer caused by Johnson & Johnson's talcum powder, citing failure to warn.
This verdict marks a key point in J&J's prolonged legal battle, addressing claims linking its talc-based products to ovarian cancer and mesothelioma.
J&J replaced talc with cornstarch in North America in 2020 and stopped global talc-based powder sales in 2023, driven by declining sales and legal pressure.
The healthcare company plans to appeal the recent jury's verdict and the compensatory damages awarded, continuing its defense against these product liability claims.
This case follows other setbacks for J&J, including a $966 million award for a mesothelioma death and the denial of a $9 billion talc settlement plan in April.
Analysis
Center-leaning sources cover this story neutrally, presenting a balanced account of the jury's verdict against Johnson & Johnson. They include both the plaintiffs' claims and J&J's immediate rebuttal, intention to appeal, and scientific defense. The reporting provides necessary context without favoring either side, allowing readers to form their own conclusions.